Viewing nowCombinationYugenta Duo Tablets 2.5/500 mg
Linagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
(Co., Ltd.) Yu Young Pharmaceutical

MFDS item code 201900304 · Approved 2019.01.22
Improvement of blood glucose control in adults with type 2 diabetes mellitus
This medication is used primarily in conjunction with meal and exercise therapy to improve blood sugar control in patients with type 2 diabetes. It can be administered when there has been no previous experience with diabetes medication and blood sugar control is difficult with monotherapy. It is also used when replacing a combination of linagliptin and metformin, and may be administered with insulin if blood sugar control is insufficient with insulin and metformin. Finally, when blood sugar control is not achieved with a combination therapy of maximum dose metformin and empagliflozin, this medication may be used in conjunction with empagliflozin. This medication helps improve blood sugar control in various therapeutic situations.
The dose of this medication should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medication should be administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior experience with diabetes medication and inadequate glycemic control with monotherapy, the initial dose of this medication is 1 tablet of 2.5/500 mg twice daily. The dose may be increased to 1 tablet of 2.5/1000 mg twice daily. 2. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medication should take an initial dose equivalent to the doses of linagliptin and metformin they were previously taking. 3. Patients with inadequate glycemic control with combination therapy of insulin and metformin: The initial dose of this medication should be considered to be similar to linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient’s existing metformin dose. When this medication is administered in combination with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Use with Caution in the Following Patients). No studies have been conducted to evaluate the safety and efficacy of switching to this medication in patients previously treated with other oral hypoglycemic agents. Any change in the treatment regimen for type 2 diabetes may cause changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dosage adjustment. Treatment should not be initiated with this medication, as the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medication should be discontinued immediately. Patients with hepatic impairment This medication should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).
This medication can cause a rare but serious side effect called lactic acidosis, so it should not be administered to patients with impaired kidney function or to those with heart disease or liver dysfunction. Patients who are allergic to any ingredient in this medication, type 1 diabetes patients, patients with acute myocardial infarction or heart failure, and women who are pregnant or breastfeeding should not use this medication. When using this medication, be alert for symptoms of hypoglycemia, especially when taken in combination with other hypoglycemic agents or insulin. Elderly patients with decreased kidney function or those with acute illness should undergo kidney function testing before administering this medication and should be regularly monitored. If iodinated contrast is used during radiological examinations, renal function may worsen, so this medication should be discontinued before and after the examination, and resumed only after kidney function stabilizes. Patients about to undergo surgery should stop taking this medication 48 hours prior to surgery and resume only after ensuring that kidney function has returned to normal. Acute pancreatitis, severe joint pain, or blistering skin conditions may occur while taking this medication; if these occur, consult a doctor immediately. Long-term use may lead to decreased vitamin B12 levels, so patients with anemia or neurological symptoms should be tested for vitamin B12 levels and receive supplementation if necessary. This medication increases the risk of lactic acidosis when taken with alcohol, so it is advisable to avoid drinking. Women who are pregnant or planning to become pregnant should preferably not use this medication and should consider alternative methods for blood sugar control. It should not be administered to children under 10 years old since safety and efficacy have not been established, and caution should be exercised when administering it to adolescents aged 10 to 17 years. Elderly patients are prone to decreased kidney function, so therapy should start at the minimum dose, with regular monitoring of kidney function. There is no available data on the effects of driving or operating machinery, so caution is needed when taking this medication. In case of overdose, the medication should be removed from the gastrointestinal tract, and if lactic acidosis occurs, immediate hospital treatment is needed, with hemodialysis being the most effective treatment method. This medication should be stored in a closed container to avoid moisture and direct sunlight, and it should be kept out of reach of children, ensuring not to transfer it to another container.
Lactic acidosis, hypoglycemia, nasopharyngitis, hypersensitivity, angioedema, urticaria, decreased and deficiency of vitamin B12, taste disturbances, cough, appetite loss, diarrhea, constipation, nausea, pancreatitis, vomiting, abdominal pain, formation of oral ulcers, abnormal liver function tests, hepatitis, pruritus, erythema, rash, vesicular pemphigoid, severe and disability-associated arthralgia, rhabdomyolysis, increased lipase, increased amylase, constipation, epigastric pain, enterocolitis, bowel obstruction, gastroenteritis, herpes zoster, cystitis, acute pyelonephritis, bronchitis, vestibular neuronitis, sepsis, pneumonia, appetite loss, dehydration, hyperglycemia, cerebral infarction, speech disorders, Alzheimer’s dementia, chest pain, fever, facial edema, fatigue, chronic obstructive pulmonary disease, asthma, diabetic foot, skin lesions, liver metastasis, acute leukemia, basal cell carcinoma, non-small cell lung cancer, malignant pericardial effusion, gastric cancer, rectal cancer, pancreatic cancer, meniscus injury, pneumoconiosis, congestive heart failure, angina pectoris, acute myocardial infarction, unstable angina, cardiac arrest, diabetic retinopathy, acute kidney injury, end-stage renal disease, acute cholangitis, acute cholecystitis, cholangitis, dizziness, kidney transplant failure, anxiety, mood disorder, insomnia, depression, contusion, bone contusion, concussion, bone fracture, hand fracture, pruritus, hypertension, benign prostatic hyperplasia, angina pectoris, acute myocardial infarction, unstable angina, stomatitis, mediastinitis, vitreous hemorrhage, fever, ligament sprain, flank pain, myelodysplastic syndrome, vocal cord polyp, dyspepsia, rectal bleeding, cheilitis, dental caries, enteritis, gastritis, gingivitis, increased blood creatinine, facial edema, hyperthermia, back pain, osteoarthritis, limb pain, rotator cuff syndrome, dizziness, diabetic neuropathy, headache, subdural effusion, palpitations, dry eye, cataract, eye discomfort, allergic conjunctivitis, nocturia, dermatitis, hypertension, hearing loss, erectile dysfunction, thyroid enlargement, altered mental state
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to air and moisture, so it must be stored in a tightly sealed container. It is best to maintain storage temperatures between 1 degree and 30 degrees Celsius at room temperature. This will help preserve the medication's effectiveness over time.
Bright yellow, bilaterally convex oval-shaped film-coated tablet
60 tablets (10 tablets/PTP packaging x 6)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationLinagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
(Co., Ltd.) Yu Young Pharmaceutical
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Anguk Pharm Co., Ltd.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Prescription medication · Combination
Hanmi Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Kukje Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
International Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.